- Home
- ICCM vs ALXO Comparison
ICCM vs ALXO Comparison
Compare ICCM & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- ALXO
- Stock Information
- Founded
- ICCM 2006
- ALXO 2015
- Country
- ICCM Israel
- ALXO United States
- Employees
- ICCM N/A
- ALXO N/A
- Industry
- ICCM
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- ALXO Health Care
- Exchange
- ICCM Nasdaq
- ALXO Nasdaq
- Market Cap
- ICCM 70.1M
- ALXO 76.5M
- IPO Year
- ICCM N/A
- ALXO 2020
- Fundamental
- Price
- ICCM $1.24
- ALXO $0.60
- Analyst Decision
- ICCM Strong Buy
- ALXO Strong Buy
- Analyst Count
- ICCM 1
- ALXO 6
- Target Price
- ICCM $2.50
- ALXO $4.14
- AVG Volume (30 Days)
- ICCM 340.9K
- ALXO 1.4M
- Earning Date
- ICCM 03-27-2025
- ALXO 03-06-2025
- Dividend Yield
- ICCM N/A
- ALXO N/A
- EPS Growth
- ICCM N/A
- ALXO N/A
- EPS
- ICCM N/A
- ALXO N/A
- Revenue
- ICCM $3,291,000.00
- ALXO N/A
- Revenue This Year
- ICCM $75.63
- ALXO N/A
- Revenue Next Year
- ICCM $69.36
- ALXO N/A
- P/E Ratio
- ICCM N/A
- ALXO N/A
- Revenue Growth
- ICCM 1.92
- ALXO N/A
- 52 Week Low
- ICCM $0.48
- ALXO $0.57
- 52 Week High
- ICCM $1.66
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- ICCM 46.87
- ALXO 30.55
- Support Level
- ICCM $1.04
- ALXO $0.59
- Resistance Level
- ICCM $1.25
- ALXO $0.72
- Average True Range (ATR)
- ICCM 0.10
- ALXO 0.06
- MACD
- ICCM -0.01
- ALXO -0.00
- Stochastic Oscillator
- ICCM 40.82
- ALXO 8.19
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.